Arbutus Biopharma Corporation (ABUS) Social Stream



Arbutus Biopharma Corporation (ABUS): $2.26

-0.14 (-5.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ABUS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 393

in industry

Arbutus Biopharma Corp (ABUS) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering ABUS.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-08 5 $9 $4 $6 $2.98 101.34%
2021-12-02 5 $9 $4 $6.625 $2.98 122.32%
2021-12-29 5 $9 $4 $6.1 $2.98 104.7%
2022-02-02 5 $9 $4 $6.3 $2.98 111.41%
2022-03-03 4 $9 $5 $6.875 $2.98 130.7%
2022-03-07 4 $9 $5 $7 $2.98 134.9%
2022-03-14 4 $9 $5 $7.125 $2.98 139.09%

The Trend in the Analyst Price Target


ABUS's average price target has moved up $1.05 over the prior 42 weeks.

ABUS reports an average of 94.42% for its upside potential over the past 49 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-05-22 3 10 3.5 6.07 2.74 121.53%
2021-07-03 7 10 3.5 6.07 2.95 105.76%
2021-08-07 7 10 3.5 5.92 3.01 96.68%
2021-08-28 6 10 3.5 5.90 3.33 77.18%
2021-09-11 6 10 3.5 5.90 4.38 34.7%

ABUS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 4 0 0 0 0 4

The Trend in the Broker Recommendations


ABUS's average broker recommendation rating improved by 1.14 over the prior 35 weeks.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ABUS as an investment opportunity.

  • In the context of all US stocks, Arbutus Biopharma Corp's average analyst price target is greater than 32.8% of them.
  • ABUS has a lower variance in analysts' estimates than -465.21% of all US stocks.
  • To contextualize these metrics, consider that out of Healthcare stocks, Arbutus Biopharma Corp's number of analysts covering the stock is higher than 216.12% of them.
  • Arbutus Biopharma Corp's upside potential (average analyst target price relative to current price) is higher than 266.44% of Pharmaceutical Products stocks.

Stocks similar to Arbutus Biopharma Corp in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ABEO, VIGL, and TCRX.

What is the outlook for ABUS? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6628 seconds.